However, with the latest success of immunotherapy in other cancers, a number of clinical studies investigating the combination of PD-1/PD-L1 inhibitors with standard-of-care therapies for GBM patients have been actively pursued. The gene discussed is PDCD1; the disease is glioblastoma.